How optimizing RBQM risk detection reduces the efforts caused by false signals.
Jonathan Rowe, PhD, MS, MA
Advertisement
Jonathan Rowe, PhD, MS, MA, has worked in the pharmaceutical industry across clinical, quality and corporate teams for over 25 years. He currently leads ZS’s clinical development quality, operations and risk management functions from the New York office.
Articles by Jonathan Rowe, PhD, MS, MA
Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.
Optimizing feasibility through increased data collection.
Applied Clinical Trials
A case study by Pfizer & The Avoca Group on the development of an overarching strategy for Pfizer’s clinical trial quality metrics.
Advertisement
Latest Updated Articles
The Eradication of False Signals in MonitoringSeptember 7th 2022
Quality Metrics for Clinical TrialsJuly 8th 2015
- Towards Data-Driven Clinical Trial Planning and Strategy
December 16th 2021
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
5